I also went back and re-read the phase II results after GRAS decision.
Re-reading the report, I also was reasonably impressed - the phase II was a tough test... effective dosage looks easily manageable within a food product.
One question I would have is how much it costs to produce and could be supplied at. This is probably more critical in a food application than in a pharmaceutical one. After that, it may be a matter of time to market, given the requirement for shelf-life testing.
- Forums
- ASX - By Stock
- CZD
- aod9604 - efficacy and marketing
aod9604 - efficacy and marketing, page-3
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)